Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW.

Trends Cancer. 2019 May;5(5):308-324. doi: 10.1016/j.trecan.2019.03.005. Epub 2019 Apr 30. Review.

PMID:
31174843
2.

Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk.

Bunch BL, Ma Y, Attwood K, Amable L, Luo W, Morrison C, Guru KA, Woloszynska-Read A, Hershberger PA, Trump DL, Johnson CS.

Cancer Med. 2019 May;8(5):2449-2461. doi: 10.1002/cam4.2119. Epub 2019 Apr 10.

3.

Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis.

Vincent-Chong VK, DeJong H, Attwood K, Hershberger PA, Seshadri M.

Neoplasia. 2019 Apr;21(4):376-388. doi: 10.1016/j.neo.2019.02.002. Epub 2019 Mar 13.

4.

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.

Liu C, Shaurova T, Shoemaker S, Petkovich M, Hershberger PA, Wu Y.

Mol Pharm. 2018 Aug 6;15(8):3216-3226. doi: 10.1021/acs.molpharmaceut.8b00307. Epub 2018 Jun 26.

PMID:
29902012
5.

Impact of Age on Disease Progression and Microenvironment in Oral Cancer.

Vincent-Chong VK, DeJong H, Rich LJ, Patti A, Merzianu M, Hershberger PA, Seshadri M.

J Dent Res. 2018 Oct;97(11):1268-1276. doi: 10.1177/0022034518775736. Epub 2018 May 11.

6.

Phase I study of veliparib in combination with gemcitabine.

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2.

7.

Flavourings significantly affect inhalation toxicity of aerosol generated from electronic nicotine delivery systems (ENDS).

Leigh NJ, Lawton RI, Hershberger PA, Goniewicz ML.

Tob Control. 2016 Nov;25(Suppl 2):ii81-ii87. doi: 10.1136/tobaccocontrol-2016-053205. Epub 2016 Sep 15.

8.

Vitamin D3 intake modulates diaphragm but not peripheral muscle force in young mice.

Ray AD, Personius KE, Williamson DL, Dungan CM, Dhillon SS, Hershberger PA.

J Appl Physiol (1985). 2016 May 15;120(10):1124-31. doi: 10.1152/japplphysiol.00643.2015. Epub 2016 Mar 10.

9.

Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.

Verone-Boyle AR, Shoemaker S, Attwood K, Morrison CD, Makowski AJ, Battaglia S, Hershberger PA.

Oncotarget. 2016 Jan 5;7(1):995-1013. doi: 10.18632/oncotarget.6493.

10.

Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model.

Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS.

Cancer Prev Res (Phila). 2015 Oct;8(10):895-904. doi: 10.1158/1940-6207.CAPR-14-0403. Epub 2015 Aug 14.

11.

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

Parise RA, Eiseman JL, Clausen DM, Kicielinski KP, Hershberger PA, Egorin MJ, Beumer JH.

Cancer Chemother Pharmacol. 2015 Sep;76(3):537-46. doi: 10.1007/s00280-015-2828-2. Epub 2015 Jul 21.

12.

Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.

Bothwell KD, Shaurova T, Merzianu M, Suresh A, Kuriakose MA, Johnson CS, Hershberger PA, Seshadri M.

Cancer Prev Res (Phila). 2015 Sep;8(9):765-76. doi: 10.1158/1940-6207.CAPR-14-0454. Epub 2015 Jun 22.

13.

A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells.

Bakkenist CJ, Czambel RK, Hershberger PA, Tawbi H, Beumer JH, Schmitz JC.

Oncoscience. 2015 May 14;2(5):542-54. eCollection 2015.

14.

1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment.

Upadhyay SK, Verone A, Shoemaker S, Qin M, Liu S, Campbell M, Hershberger PA.

Cancers (Basel). 2013 Nov 8;5(4):1504-21. doi: 10.3390/cancers5041504.

15.

24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics.

Luo W, Hershberger PA, Trump DL, Johnson CS.

J Steroid Biochem Mol Biol. 2013 Jul;136:252-7. doi: 10.1016/j.jsbmb.2012.09.031. Epub 2012 Oct 8. Review.

16.

CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.

Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, Lin Y, Diergaarde B, Hershberger PA.

Mol Cell Endocrinol. 2012 May 15;355(1):153-61. doi: 10.1016/j.mce.2012.02.006. Epub 2012 Feb 22.

17.

A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay.

Beumer JH, Parise RA, Kanterewicz B, Petkovich M, D'Argenio DZ, Hershberger PA.

Steroids. 2012 Apr;77(5):477-83. doi: 10.1016/j.steroids.2012.01.007. Epub 2012 Jan 20.

18.

Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer.

Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL.

J Steroid Biochem Mol Biol. 2011 Jan;123(1-2):30-6. doi: 10.1016/j.jsbmb.2010.10.002. Epub 2010 Oct 16.

19.

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6. Epub 2010 May 5.

20.

Estrogen receptor signaling in lung cancer.

Siegfried JM, Hershberger PA, Stabile LP.

Semin Oncol. 2009 Dec;36(6):524-31. doi: 10.1053/j.seminoncol.2009.10.004.

21.

The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis.

Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E.

J Histochem Cytochem. 2010 Mar;58(3):277-85. doi: 10.1369/jhc.2009.954339. Epub 2009 Nov 9.

22.

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA.

Int J Cancer. 2010 Feb 1;126(3):743-55. doi: 10.1002/ijc.24759.

23.

Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.

Nichols M, Cheng P, Liu Y, Kanterewicz B, Hershberger PA, McCarty KS Jr.

Breast Cancer Res Treat. 2010 Apr;120(3):761-8. doi: 10.1007/s10549-009-0437-7. Epub 2009 Jun 13.

PMID:
19526339
24.

Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.

Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, Shuai Y, Siegfried JM, Nichols M.

J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):102-9. doi: 10.1016/j.jsbmb.2009.05.004. Epub 2009 May 19.

25.

1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS.

Mol Cancer Ther. 2008 Sep;7(9):3047-55. doi: 10.1158/1535-7163.MCT-08-0243.

26.

The antitumor efficacy of calcitriol: preclinical studies.

Johnson CS, Muindi JR, Hershberger PA, Trump DL.

Anticancer Res. 2006 Jul-Aug;26(4A):2543-9. Review.

27.

CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer.

Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T, Hershberger PA.

Int J Cancer. 2006 Oct 15;119(8):1819-28.

28.

Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.

Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M.

Cancer Res. 2005 Feb 15;65(4):1598-605.

29.

Inhibition of estrogen receptor alpha-mediated transcription by antiestrogenic 1,1-dichloro-2,2,3-triarylcyclopropanes.

Cheng P, Kanterewicz B, Hershberger PA, McCarty KS Jr, Day BW, Nichols M.

Mol Pharmacol. 2004 Oct;66(4):970-7. Epub 2004 Jul 2.

PMID:
15235102
30.

Anti-tumor activity of calcitriol: pre-clinical and clinical studies.

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS.

J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26. Review.

PMID:
15225831
31.

C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells.

Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA.

Prostate. 2003 Sep 15;57(1):66-79.

PMID:
12886525
32.

Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.

Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL.

Clin Pharmacol Ther. 2002 Dec;72(6):648-59.

PMID:
12496746
33.

Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.

Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL, Johnson CS.

Mol Cancer Ther. 2002 Aug;1(10):821-9.

34.

Vitamin D-related therapies in prostate cancer.

Johnson CS, Hershberger PA, Trump DL.

Cancer Metastasis Rev. 2002;21(2):147-58. Review.

PMID:
12465754
35.

Vitamin D receptor: a potential target for intervention.

Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL.

Urology. 2002 Sep;60(3 Suppl 1):123-30; discussion 130-1. Review.

PMID:
12231068
36.
37.

Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.

Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL.

Clin Cancer Res. 2001 Apr;7(4):1043-51.

38.

1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo.

Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS.

Cancer Res. 1999 Jun 1;59(11):2644-9.

39.

Down-modulation of a novel Bax-associated protein during apoptosis in normal mature B lymphocytes.

He H, Hershberger PA, McCarthy SA.

J Immunol. 1998 Aug 1;161(3):1176-82.

40.
41.

In vitro thymocyte maturation is associated with reduced cellular susceptibility to Fas-mediated apoptosis.

Hershberger PA, He H, McCarthy SA.

Cell Immunol. 1998 May 1;185(2):134-45.

PMID:
9636691
42.

Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation.

Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW.

J Immunol. 1997 Jun 15;158(12):5676-84.

PMID:
9190916
44.
45.

Interference by PR-bound RNA polymerase with PRM function in vitro. Modulation by the bacteriophage lambda cI protein.

Hershberger PA, Mita BC, Tripatara A, deHaseth PL.

J Biol Chem. 1993 Apr 25;268(12):8943-8.

Supplemental Content

Loading ...
Support Center